Prostate Cancer Nuclear Medicine Diagnostics Industry Insights 2025 – Market Forecast for Executives and Planners
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has The Prostate Cancer Nuclear Medicine Diagnostics Market Size Shifted, And What Is the Outlook Through 2034?_x000D_
The market size for nuclear medicine diagnostics in prostate cancer has seen rapid enlargement in the past few years. Expected to expand from $0.86 billion in 2024 to $0.99 billion in 2025, it boasts a compound annual growth rate (CAGR) of 15.0%. The historical growth is linked to factors such as rising demand for pet scans, urbanization and growth in disposable income, coupled with the increased necessity for precise cancer diagnosis and a strong emphasis on early detection._x000D_
_x000D_
#How Much Will the Prostate Cancer Nuclear Medicine Diagnostics Market Be Worth in 2029?#_x000D_
The market for nuclear medicine diagnostics for prostate cancer is projected to witness substantial expansion in the forthcoming years. This market is set to grow to $1.71 billion by the year 2029 with a 14.6% compound annual growth rate (CAGR). The expected growth during this period is due in part to the escalating incidences of prostate cancer, an increased demand for positron emission tomography, heightened awareness regarding environmental sustainability, mounting instances of diverse cancers, and enhanced digital transformation. The forecast period will also see significant trends including product innovation, technological progress, advancements in nuclear medicine imaging, improvement in radiopharmaceuticals and imaging methodologies, and innovation in radiopharmaceuticals._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=15906&type=smp_x000D_
_x000D_
#Which is the Largest Company in the Prostate Cancer Nuclear Medicine Diagnostics Market?#_x000D_
Major companies operating in the prostate cancer nuclear medicine diagnostics market are Cardinal Health, General Electric, Bayer AG, Novartis AG, Siemens Healthineers AG, GE Healthcare, Lantheus, CURIUM PHARMA, Telix Pharmaceuticals Ltd., Eckert & Ziegler AG, Point Biopharma Global Inc., Point Biopharma, Alliance Medical Ltd., SHINE Medical Technologies LLC, PETNET Solution, NorthStar Medical Radioisotopes LLC, Global Medical Solutions LLC, Isotope Technologies Garching (ITG), Jubilant Pharma Limited, Blue Earth Diagnostics Inc., Institute of Isotopes Co. Ltd., Radiopharm Theranostics, Bracco Diagnostic Inc., NCM-USA LLC, ABX Advanced Biochemical Compounds GmbH_x000D_
_x000D_
#What Are the Main Market Drivers in the Prostate Cancer Nuclear Medicine Diagnostics Industry?#_x000D_
The escalating occurrence of prostate cancer is anticipated to drive the growth of the prostate cancer nuclear medicine diagnostics market in the future. Prostate cancer develops in the prostate, a minuscule gland shaped like a walnut in males, responsible for producing seminal fluid that nourishes and transports sperms. The growing incidence of prostate cancer can be attributed to an aging demographic, changes in lifestyle, and genetic predispositions. Nuclear medicine diagnostics brings significant insights into prostate cancer, thereby enabling medical clinicians to provide more precise, effective, and personalized care to prostate cancer patients. Notably, the World Health Organization, a public health agency based in Switzerland, stated in February 2024 that over 35 million new cancer cases are predicted by 2050, which signals a 77% increase from the anticipated 20 million cases in 2022. Hence, the increasing prevalence of prostate cancer propels the growth of the prostate cancer nuclear medicine diagnostics market._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=15906&type=smp_x000D_
_x000D_
#How Is the Prostate Cancer Nuclear Medicine Diagnostics Market Segments Structured?#_x000D_
The prostate cancer nuclear medicine diagnostics market covered in this report is segmented –_x000D_
_x000D_
1) By Type: Single Photon Emission Computed Tomography (SPECT), Photon Emission Computed Tomography (PET)_x000D_
2) By Test Type: Preliminary Tests, Confirmatory Tests_x000D_
3) By End User: Hospitals, Clinics, Other End Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Single Photon Emission Computed Tomography (SPECT): Gamma Camera SPECT, Hybrid SPECT Or CT Imaging_x000D_
2) By Positron Emission Tomography (PET): PET Or CT Imaging, PET Or MRI Imaging_x000D_
_x000D_
#What Strategic Trends Are Transforming the Prostate Cancer Nuclear Medicine Diagnostics Market?#_x000D_
Major businesses in the prostate cancer nuclear medicine diagnostics market are advancing novel diagnostic imaging methods and acquiring approval from the US Food and Drug Administration (FDA). FDA approval for such diagnostics guarantees the secure and functional availability of tests for healthcare providers and patients, aiding in the diagnosis and management of a wide range of medical conditions. As an exemplification, Novartis, a pharmaceutical giant hailing from Switzerland, introduced Pluvicto(lutetium Lu 177 vipivotide tetraxetan) in March 2022. This newly launched product provides treatment to adult patients who have been diagnosed with metastatic castration-resistant prostate cancer (mCRPC), specifically the type known as prostate-specific membrane antigen-positive (PSMA-positive) that has spread elsewhere in the body. Pluvicto unites a targeting compound (ligand) with a therapeutic radioisotope, serving as a precision treatment to attack prostate cancer cells that express the prostate-specific membrane antigen (PSMA)._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#Which Global Regions Offer the Highest Growth in the Prostate Cancer Nuclear Medicine Diagnostics Market?#_x000D_
North America was the largest region in the prostrate cancer nuclear medicine diagnostics market in 2023. The regions covered in the prostate cancer nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15906_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the prostate cancer nuclear medicine diagnostics market, and how is it changing globally?_x000D_
2. Who are the major companies in the prostate cancer nuclear medicine diagnostics market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the prostate cancer nuclear medicine diagnostics market right now?_x000D_
4. Which products or customer segments are growing the most in the prostate cancer nuclear medicine diagnostics market?_x000D_
5. What factors are helping or slowing down the growth of the prostate cancer nuclear medicine diagnostics market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 2071930708_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
